Rhythm Pharmaceuticals (NASDAQ:RYTM) focuses on developing and commercializing therapies for people living with rare genetic diseases of obesity. Primarily engaging in the discovery, research, and development of innovative pharmaceuticals, Rhythm aims to address the unmet needs of patients suffering from these complex conditions. The company's leading project involves the peptide-1 (MC4R) agonist, setmelanotide, targeted at treating a spectrum of rare genetic disorders that contribute to obesity. Through its dedicated efforts, Rhythm seeks not only to advance its pipeline of transformative treatments but also to enhance understanding and management of rare obesity disorders, ultimately striving to improve patients' lives worldwide.